For research use only. Not for therapeutic Use.
Ribociclib (LEE011)(Cat No.:I000792) is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which are enzymes that play a role in the regulation of the cell cycle. By inhibiting these enzymes, Ribociclib can help to slow or stop the growth of cancer cells. Ribociclib is typically used in combination with other drugs, such as hormonal therapies, for the treatment of hormone receptor-positive, HER2-negative advanced, or metastatic breast cancer in postmenopausal women. It may also be used in certain other types of cancer, including neuroblastoma.
| Catalog Number | I000792 |
| CAS Number | 1211441-98-3 |
| Synonyms | Ribociclib; LEE011; 7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide |
| Molecular Formula | C23H30N8O |
| Purity | ≥95% |
| Target | Cyclin-Dependent Kinases |
| Solubility | DMSO: ≥ 4.3 mg/mL, DMSO: ＜ 8.4 mg/mL |
| Storage | Store at -20°C |
| Overview of Clinical Research | Ribociclib(LEE011) is an orally available cyclin-dependent kinase (CDK) 4 inhibitor as well as CDK 6 inhibitor. The phase II study for breast cancer is ongoing. |
| IC50 | 307 ± 68 nM (neuroblastoma-derived cell lines) |
| IUPAC Name | 7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide |
| InChI | InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28) |
| InChIKey | RHXHGRAEPCAFML-UHFFFAOYSA-N |
| SMILES | CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5 |
| Reference | 1: Kwapisz D. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib. Breast Cancer Res Treat. 2017 Nov;166(1):41-54. doi: 10.1007/s10549-017-4385-3. Epub 2017 Jul 24. Review. PubMed PMID: 28741274.<br /> |
